G2TT
来源类型Perspectives
规范类型论文
DOIhttps://doi.org/10.7249/PE264
来源IDPE-264-SANI
Biosimilar Cost Savings in the United States: Initial Experience and Future Potential
Andrew W. Mulcahy; Jakub P. Hlavka; Spencer R. Case
发表日期2017
出版年2017
页码20
语种英语
结论

The Cost Savings Potential of Biosimilars

  • We estimated the cost savings potential of biosimilars to be $54 billion over ten years using recent baseline data and transparent assumptions, with a lower- to upper-bound range of $25 billion to $150 billion.
  • The potential for cost savings will vary across biologic classes based on sales, the degree of competition, and the timing of biosimilar entry into the market.

The Future of the Biosimilars Market

  • Evolving payment arrangements, regulatory policies and guidance, patient and prescriber acceptance of biosimilars, and other factors will influence the magnitude of potential savings.

The Beneficiaries of Cost Savings

  • Savings will accrue to a range of stakeholders in the short term, although patients and taxpayers will benefit in the long term.
摘要

The Biologics Price Competition and Innovation Act (BPCIA), enacted as part of the 2010 Patient Protection and Affordable Care Act (ACA), authorized the U.S. Food and Drug Administration (FDA) to create a new regulatory approval pathway for biosimilars, which are biologic drugs that are very similar to already approved "reference" biologics in terms of potency, safety, and efficacy, but are manufactured by different companies. In the seven years since the ACA, many drug manufacturers worked to push new biosimilars through development and FDA review. As of July 2017, there were three marketed biosimilars and two more that were approved by the FDA but not yet marketed. BPCIA's shorter, lower-cost biosimilar approval pathway was designed to introduce competition among biologic manufacturers.

This Perspective estimates potential future savings from biosimilars in the United States, summarizes the experience to date with the first marketed biosimilar in the United States, and discusses key policy issues surrounding biosimilars. We estimate that biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3 percent of total estimated biologic spending over the same period, with a range of $24 to $150 billion. While our estimate uses recent data and transparent assumptions, we caution that actual savings will hinge on industry and regulatory decisions as well as potential policy changes to strengthen the biosimilar market.

主题Health Care Costs ; Health Economics ; Health Insurance ; Pharmaceutical Drugs
URLhttps://www.rand.org/pubs/perspectives/PE264.html
来源智库RAND Corporation (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/112570
推荐引用方式
GB/T 7714
Andrew W. Mulcahy,Jakub P. Hlavka,Spencer R. Case. Biosimilar Cost Savings in the United States: Initial Experience and Future Potential. 2017.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
x1545057977126.jpg(8KB)智库出版物 限制开放CC BY-NC-SA浏览
RAND_PE264.pdf(243KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Andrew W. Mulcahy]的文章
[Jakub P. Hlavka]的文章
[Spencer R. Case]的文章
百度学术
百度学术中相似的文章
[Andrew W. Mulcahy]的文章
[Jakub P. Hlavka]的文章
[Spencer R. Case]的文章
必应学术
必应学术中相似的文章
[Andrew W. Mulcahy]的文章
[Jakub P. Hlavka]的文章
[Spencer R. Case]的文章
相关权益政策
暂无数据
收藏/分享
文件名: x1545057977126.jpg
格式: JPEG
文件名: RAND_PE264.pdf
格式: Adobe PDF

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。